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► non–vitamin K oral
anticoagulants
Abstract Background Dutch guidelines advise extended anticoagulant treatment with direct
oral anticoagulants or vitamin K antagonists for patients with idiopathic venous
thromboembolism (VTE) who do not have high bleeding risk.
Objectives The aim of this study was to analyze the economic effects of extended
treatment of apixaban in the Netherlands, based on an updated and adapted previously
published model.
Methods We performed a cost-effectiveness analysis simulating a population of 1,000
VTE patients. The base-case analysis compared extended apixaban treatment to no
treatment after the ﬁrst 6 months. Five additional scenarios were conducted to evaluate
the effect of different bleeding risks and health care payers’ perspective. The primary
outcome of the model is the incremental cost-effectiveness ratio (ICER) in costs (€) per
quality-adjusted life-year (QALY), with one QALY deﬁned as 1 year in perfect health. To
account for any inﬂuence of the uncertainties in the model, probabilistic and univariate
sensitivity analyses were conducted. The treatment was considered cost-effective with an
ICER less than €20,000/QALY, which is the most commonly used willingness-to-pay (WTP)
threshold for preventive drugs in the Netherlands.
Results The model showed a reduction in recurrent VTE and no increase in major
bleeding events for extended treatment in all scenarios. The base-case analysis showed an
ICER of €9,653/QALY. The probability of being cost-effective for apixaban in the base-
case was 70.0% and 91.4% at a WTP threshold of €20,000/QALY and €50,000/QALY,
respectively.
Conclusion Extended treatment with apixaban is cost-effective for the prevention of
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Venous thromboembolism (VTE) can occur in the form of
deep venous thrombosis (DVT) or pulmonary embolism (PE).
In 2015, almost 86,000 patients were registered for treat-
ment of VTE at the Dutch Thrombosis Service.1 Patients who
experienced VTE are more likely to develop recurrent VTE
over time. Research has shown that in patients with idio-
pathic VTE, the occurrence of a recurrent VTE is 11% after the
ﬁrst year and up to 40% in the 10 years after the ﬁrst event.2
Currently, the standard treatment for VTE is daily treatment
with direct oral anticoagulants (DOACs) for at least 3months,
or a 5- to 7-day treatment with low-molecular-weight
heparin (LMWH) followed by at least a 3-month course of
vitamin K antagonists (VKAs).3,4 This advice has recently
been implemented in the Dutch guidelines for general prac-
titioners (NHG, Dutch: Nederlands Huisartsen Genootschap)
aswell.5,6 The duration of treatment is determined by several
factors including the exact cause of the thromboembolic
episode and the patient’s bleeding risk. A meta-analysis
incorporated in the UK’s National Institute for Health and
Care Excellence (NICE) guideline shows a decrease in VTE
recurrencewhen patients were treated for 6months or more
comparedwith 3months.7However, it is also stated that this
prolonged treatment may increase the risk of bleeding.
The thromboembolic and bleeding effects of various antic-
oagulation periods were also examined among different
anticoagulant drugs. The Apixaban for the Initial Manage-
ment of Pulmonary Embolism and Deep-Vein Thrombosis as
First-Line Therapy (AMPLIFY) trial compared the efﬁcacy and
safety of the DOAC apixaban to LMWH followed by the VKA
warfarin in the treatment of VTE.8 Apixaban, given in a dose
of 10 mg twice daily for 7 days followed by 5 mg twice a day
for a total of 6 months, was noninferior in the prevention of
recurrent VTE and statistically signiﬁcantly safer than VKA.
In the AMPLIFYextension (AMPLIFY-EXT) trial, after an initial
course of 3 to 12months of anticoagulant treatment patients
were given either 2.5 or 5 mg apixaban twice daily or placebo
for another 12 months.9 Both doses showed a statistically
signiﬁcant reduction in recurrent thromboembolic events
(fatal or nonfatal), while therewas no statistical difference in
risk of major bleeding (MB) compared with placebo.
Owing to the results of various studies, the American
College of Chest Physicians (ACCP) guidelines suggest
extended treatment for patients experiencing an unpro-
voked VTE with a low to moderate bleeding risk,3 which is
endorsed by the Dutch guidelines.4
As stated earlier, the extended use of apixaban will result
in a decrease of recurrent VTE events. Therefore,wehypothe-
size that treatment with apixaban in VTE patients might
prevent hospitalizations and chronic complications, such as
chronic thromboembolic pulmonary hypertension (CTEPH)
and postthrombotic syndrome (PTS), which are associated
with high costs. Moreover, prevention of these events avoids
decreases in the patients’ quality of life (QoL). Obviously,
additional potential bleeding events, as well as the drug
costs, should be taken into account when choosing the
optimal treatment strategy. It is important to provide an
overview of these costs and beneﬁts, within the framework
of a cost-effectiveness model. The aim of the study was to
explore the clinical and economic consequences of extended
treatment with apixaban versus no extended treatment in
the Netherlands, based on an updated and adapted, pre-




We performed a cost-effectiveness analysis (CEA) using a
Markov model. The structure of the model was in essence
the same as our previously published model used for cost-
effectiveness for acute (6 months) treatment of VTE.10
►Supplementary Fig. S1 outlines the structure of the model,
in which patients were able to move through 12 different
health states. All patients entered themodel either in the index
DVT (66%) or the index PE (34%) state.9 Since we wanted to
calculate the cost-effectiveness over lifetime, we modeled a
hypothetical population of 1,000 patients who were able to
move among the 12 health states: recurrent VTE (recurrent PE
or DVT), VTE-related death, MB, clinically relevant nonmajor
bleed (CRNMB), CTEPH, death from other causes (background
mortality), treatment discontinuation, or no event. In addition
to the health states listed earlier, PTS is modeled in the back-
ground, so that costs and utility decrements associated with
PTSwere also taken into account. Themodel allows patients to
move among the different health states with a 3-month cycle
length. Transition probabilities reﬂect the patients’ chances to
move among these different health states within the cycle
length. The transition probabilities for the ﬁrst six cycles (18
months) were based on the AMPLIFY trials.8,9 The consecutive
cycles were based on real-world data, since the AMPLIFY trials
had a follow-up time of only 18 months.11 Subsequently, we
calculated per cycle the number of patients in each health state
andmultiplied this with state-speciﬁc costs and health effects.
Health effects are calculated in quality-adjusted life-year
(QALY), with one QALY deﬁned as 1 year in perfect health.
The primary outcome of the model is the incremental cost-
effectiveness ratio (ICER) in costs (€) per QALY.
Patientswho experienced an indexVTE require anticoagula-
tion treatment and subsequent treatment for the secondary
prevention of recurrent events. Treatment duration in the
model could be varied from 6 months to lifelong, in which
theﬁrst6monthsof treatmentwasdeﬁnedas the initial (orVTE
treatment) period.8 Anticoagulation treatment in the initial
period was based on the AMPLIFY trial, comparing 5 mg
apixaban twice daily to LMWH/VKA treatment. The extended
treatment period (after 6 months of initial treatment) was
considered to model the prevention of recurrent VTE by com-
paring continued treatment with apixaban 2.5 mg twice daily
(registered dose of apixaban for this indication12) to no treat-
ment. The hypothetical model population consisted of 1,000
patients (mean age: 56.9 years, 58% male9) who had an index
VTE. Itwasassumedthat34%of thepatientshadexperiencedan
initialPEand66%hadan initialDVTevent,basedonthepatients’
characteristics reported in the AMPLIFY-EXT trial.9
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Patients were followed up over lifetime with starting age
of 56.9 years (maximum age: 100 years), receiving either
extended treatment with apixaban or no treatment. To
account for differences in MB and CRNMB between apixaban
2.5 mg and placebo in the AMPLIFY-EXT trial, additional
scenario analyses were conducted. In these scenarios, the
risks of MB, CRNMB, and MB plus CRNMB in the “no treat-
ment” arm were assumed to be equal to the risks observed
for apixaban. The following analyses were conducted:
– Base-case analysis: A CEA comparing extended treatment
with apixaban to no treatment from a societal perspec-
tive. In this base-case analysis, the initial (6 months)
treatment was explicitly excluded from the calculations.
The efﬁcacy and safety data of the two treatment strate-
gies in the model were based on the AMPLIFY-EXT study
(apixaban 2.5 mg vs. placebo).9
– Scenario analysis 1: A CEA from a societal perspective
comparing initial apixaban treatment (6 months) fol-
lowed by extended treatment with apixaban to initial
treatment with LMWH/VKAwithout extended treatment,
in which efﬁcacy and safety data were based on the
AMPLIFY and AMPLIFY-EXT trial.8,9
– Scenario analysis 2: The base-case analysis conducted
from a healthcare payers’ perspective.
– Scenario analysis 3: The base-case analysis where the risk
of MB with no treatment is equal to the risk of MB with
apixaban treatment observed in the AMPLIFY-EXT trial.
– Scenario analysis 4: Thebase-case analysis,where the riskof
CRNMBwithnotreatment isequaltotheriskofCRNMBwith
apixaban treatment observed in the AMPLIFY-EXT trial.
– Scenario analysis 5: The base-case analysis, where both
MB and CRNMB risks with no treatment are equal to the
risk with apixaban treatment observed in the AMPLIFY-
EXT trial.
Transition Probabilities
The transition probabilities used in the model for the
extended treatment period are summarized in ►Table 1.
Probabilities of the initial treatment period, used in scenario
1, can be found in our previous CEA publication on the acute
treatment of VTE with apixaban.10
Thromboembolic risks were estimated in a secondary
analysis of the AMPLIFY-EXT trial to differentiate between
different periods. The absolute risks of recurrent VTE and
VTE-related death were considered to be time dependent,
with risks presented for the extended treatment periods 6–9
months, 9–12 months, 12–15 months, and 15–18 months.
The risk during the ﬁrst 3 months (6–9 months) of extended
treatment was calculated using the number of patients
experiencing an event in the ﬁrst 3 months as the numerator
and the denominator was the intention-to-treat (ITT) popu-
lation for efﬁcacy and safety outcomes. For the subsequent
intervals (9–12 months, 12–15 months, and 15–18 months),
the risk of efﬁcacy outcomes was calculated using the
number of patients experiencing a recurrent event during
the interval of interest as the numerator and the ITT or the
modiﬁed ITT population as the denominator after censoring
patients who experienced an event in any of the preceding
3-month intervals. For risks of recurrent VTE beyond
18 months, the baseline risk from Prandoni et al is used
combined with the treatment effect from AMPLIFY-EXT on
placebo and apixaban is applied to determine risk of patients
treated with apixaban.11
The bleeding risks for the lifelong apixaban and no treat-
ment alternative used for extended treatment period are not
time dependent due to the small number of events observed
in the AMPLIFY-EXT trial.9 For bleeds that occur in the period
after 18 months, the model uses constant risks from the
placebo arm of the AMPLIFY-EXT trial, adjusted with risk
adjustment factors to account for aging.11
Risks of the chronic complications of PE and DVT, such as
CTEPH and PTS, were obtained from previously published
articles.2,15 Treatment discontinuation could occur due to
intracranial (IC), non-IC MB, or reasons unrelated to VTE and
bleeding events. It was assumed that after an IC bleed, the
treatment discontinuation was permanent.10,18 Disconti-
nuation due to non-IC MB and CRNMB was assumed to be
14 and 2 days, respectively. These are the same assumptions
as made in the previously published article on apixaban in
VTE patients.10 Treatment discontinuation unrelated to clin-
ical events was based on the AMPLIFY-EXT trial.9 General
mortality rates were based on the Dutch life tables from the
Statistic Netherlands.19
Costs and Utilities
Cost and utility parameters were the same as presented in
the previous publication of the acute treatment model
(►Supplementary Tables S1 and S2).10 The primary economic
outcome of themodel was the ICER, calculated by dividing the
difference in costs by the difference in QALYs. In the base-case
analysis, the ICERwascalculated fromasocietalperspective, as
recommended in the Dutch guidelines for cost-effectiveness
studies.20 Therefore, all relevant costswere taken into account
including indirect costs, such asproductivity losses. Scenario 2
was speciﬁcally calculated from a healthcare payers’ perspec-
tive, excluding these indirect costs. Annual discount rates for
costs and utilities of 4 and 1.5% were used, respectively.20 All
costs were updated to the year 2015.
In the extended treatment period, drug costs were based on
2.5 mg apixaban twice daily. In scenario 1, we included the
initial treatment period, which was speciﬁed as 7 days 10 mg
followed by 6 months 5 mg apixaban twice daily. This
was compared with a 5-day LMWH treatment (171 anti-Xa
IU/kg/day) and 7 days of 3.2 mg VKA (acenocoumarol, phen-
procoumon) treatmentdaily followedby2.2 mgVKAdaily.Drug
costs were obtained from the ofﬁcial Dutch price list (Z-index)
and were assigned to all the health states excluding patients in
their treatment discontinuation period as described earlier.21
Costs of PE and DVT for in- and outpatients were based on
the declaration costs published by the Dutch Healthcare
Authority.22 Other event costs, such as CTEPH, PTS, and
bleeding, are based on various previously published arti-
cles.23–26 Direct costs outside the healthcare sector referred
to travel expenses. Travel expenses were taken into account at
the occurrence of a hospital administration or visit, interna-
tionalnormalized ratio (INR)monitoring visitorahospitalvisit
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Table 1 Base-case transition probabilities used in the Markov model for the extended treatment period
Transition probability Value (95% CI) Distribution Reference
Recurrent VTE and VTE-related death
Apixaban 6–9 mo 0.0048 (0.0001–0.0094) Beta 9
Apixaban 9–12 mo 0.0059 (0.0007–0.0111) Beta 9
Apixaban 12–15 mo 0.0012 (0.0000–0.0035) Beta 9
Apixaban 15–18 mo 0.0036 (0.0000–0.0076) Beta 9
No treatment 6–9 mo 0.0277 (0.0166–0.0389) Beta 9
No treatment 9–12 mo 0.0265 (0.0156–0.0375) Beta 9
No treatment 12–15 mo 0.0217 (0.0118–0.0316) Beta 9
No treatment 15–18 mo 0.0121 (0.0046–0.0195) Beta 9
Distribution of PE, DVT, and VTE-related death
VTE-related death 0.1188 Dirichlet 9
Recurrent PE 0.2475 Dirichlet 9
Recurrent DVT 0.6337 Dirichlet 9
Cumulative incidence of risk recurrent VTE posttreatment cessation
0–1 y 0.0110 (0.0950–0.1250) Beta 11
1–3 y 0.1960 (0.1750–0.2170) Beta 11
3–5 y 0.2910 (0.2630–0.3190) Beta 11
5–10 y 0.3990 (0.3540–0.4440) Beta 11
MB (risk beyond ﬁrst 6-mo treatment)
Apixaban 0.0024 (0.0000–0.0057) Beta 9
No treatment 0.0048 (0.0001–0.0096) Beta 9
Proportion of fatal MB among MB, and nonfatal IC bleeding among nonfatal MB
Fatal major bleeding 0.1346 (0.1128–0.1580) Beta 13
Nonfatal IC bleeding 0.1397 (0.1160–0.1652) Beta 13
Risk of CRNMB (risk beyond ﬁrst 6-mo treatment)
Apixaban 0.0300 (0.0182–0.0412) Beta 9
No treatment 0.0230 (0.0128–0.0332) Beta 9
Bleeding risk adjustment factor, major
bleeding, and CRNMB (per decade)
1.970 (1.7900–2.1600) Log normal 14
Risk of treatment interruption after non-IC
bleeding (14 d)
0.4727 (0.3434–0.6039) Beta 9
Riskof treatment interruption afterCRNMB(2d) 1.0000 Fixed Assumption
Risk of other treatment discontinuation (unrelated to events included in the model)
Apixaban 0.0667 (0.0498–0.0835) Beta 9
Annual risk of CTEPH in PE patients 0.0125 (0.0003–0.0246) Beta 15
5-y risk of severe PTS in DVT patients 0.0812 (0.0500–0.1000) Beta 11
Hazard ratios mortality risks
Index DVT (HR) 4.41 (3.63–5.36) Gamma 16
Index PE (HR) 4.41 (3.63–5.36) Gamma 16
Post-IC bleed (HR) 2.60 (2.20–5.60) Gamma 11
Post-CTEPH (HR) 1.30 (0.98–1.73) Gamma 17
Abbreviations: CRNMB, clinically relevant nonmajor bleeding; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep venous
thrombosis; IC, intracranial; MB, major bleeding; PE, pulmonary embolism; VTE, venous thromboembolism.
Note: Distributions were used to conduct the probabilistic sensitivity analysis.
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for IC bleed, CTEPH, PE, or DVT event. The tariff was based on a
mean of a one-way 7-km traveling distance by car, public
transportation, and taxi, as described in the Dutch guidelines
for pharmaco-economic research.20 Indirect costs outside the
healthcare sector referred to productivity losses, calculated
with the friction cost method.20 Hourly wages and the prob-
ability of employment were based on information from the
Statistics Netherlands.19 All costs parameters are summarized
in ►Supplementary Table S1.
The health effects in the model were calculated in QALYs,
reﬂecting life-years adjusted for their utility. The baseline
utility for patients in the model referred to the average for
60- to 70-year-old Dutch men and women estimated with
the ﬁve-level version of the EQ-5D.27 Upon the (re-)occur-
rence of VTE or bleeding events, utility decrements were
applied to values speciﬁc for each health state. Utility para-
meters are presented in ►Supplementary Table S2.
Sensitivity Analysis
To account for inﬂuence of the uncertainties on the economic
outcomes of the model, sensitivity analyses were conducted.
In the probabilistic sensitivity analysis (PSA), all uncertain
parameters were simultaneously varied over their 95% con-
ﬁdence interval (CI), while calculating the ICER 2,000 times.
For event risks, multipliers, and distributions of the risks, we
used β, log normal, and Dirichlet distributions, respectively.
We used a gamma or log normal distribution for costs and β
distributions for utilities.28 All 2,000 iterations were plotted
in a cost-effectiveness plane. Subsequently, a cost-effective-
ness acceptability curve (CEAC) was obtained to show the
probability of being cost-effective at different willingness-
to-pay (WTP) thresholds. The probability of being cost-
effective based on the iterationswas subsequently calculated
in the PSA.
In the univariate sensitivity analysis (USA), we varied all
relevant parameters individually over their 95% CI to explore
which parameters had the highest inﬂuence on the ICER.
When the 95% CI was not available, a standard error of 30%
was used.28
Model Validation
Predictive validity was checked by comparing key outcomes
to the source data. In performing this validation, the model
was set to the settings of the AMPLIFY-EXT and the AMPLIFY
(i.e., number of patients, duration of follow-up) and the key
event rates were compared.
Results
The clinical results of the base-case and scenario analyses are
shown in ►Table 2 and ►Supplementary Table S3, respec-
tively. In the base-case cohort of 1,000 VTE patients in total,
310 recurrent VTE, 27 MBs, and 2 cases of CTEPH are
prevented with extended treatment compared with no
Table 2 Recurrent VTE, bleeding events, and other adverse events and corresponding costs within a hypothetical cohort of 1,000
VTE patients: the base-case results
Extended apixaban No treatment
Events, n Cost/Patient Events, n Cost/Patient
Recurrent VTE and VTE-related death
VTE-related death 35 €13 72 €31
Nonfatal recurrent PE 72 €109 149 €250
Nonfatal recurrent DVT 185 €34 382 €79
Total 292 €156 603 €360
Major bleeds
Fatal 14 €177 18 €233
Nonfatal intracranial bleed 13 €232 16 €313
Nonfatal extracranial bleed 80 €241 100 €316
Total 107 €650 134 €862
Clinically relevant nonmajor bleeds 769 €14 641 €12
CTEPH 31 €254 33 €269
Treatment discontinuation 585 50
Anticoagulant and administration costs €5,686 €84
Monitoring costs €12 €39
Indirect costs
Productivity loss €2,241 €3,847
Transportation costs €95 €227
Abbreviations: CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep venous thrombosis; PE, pulmonary embolism; VTE, venous
thromboembolism.
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treatment, based on efﬁcacy and safety data from the
AMPLIFY-EXT trial. Extended apixaban treatment increases
the number of CRNMBs and treatment discontinuation,
compared with no treatment.
The deterministic economic results are shown in►Table 3.
In the base-case scenario, lifelong apixaban treatment shows
incremental costs of €9,653 per QALY compared with no
treatment. The ﬁrst scenario shows an ICER of €8,085 per
QALY for initial apixaban treatment followed by extended
treatment, compared with initial LMWH/VKA treatment fol-
lowed by no treatment. The base-case calculated from a
healthcare payers’ perspective (scenario 2) shows an ICER of
€14,490 per QALY. Three additional scenarios (scenarios 3–5)
were conducted to explore the effect of equal bleeding risks
resulting in ICERs of €12,267, €9,648, and €12,231 per QALY,
respectively.
►Table 2 shows the number of events and the correspond-
ing costs per patient in the hypothetical population of 1,000
VTE patients. The costs per patient per event reﬂect the
number of events that occurred in thehypothetical population
multiplied by the costs of the event divided over the whole
population. MBs and productivity losses showed to have a big
contribution on total costs. In the apixaban arm, the highest
costsper patientwerespentondrug costs. Similar resultswere
found for the scenarios (►Supplementary Table S3).
ThePSA for thebase-caseanalysiswasperformedwith2,000
iterations of ICER calculation,which is displayed in►Fig. 1. The
corresponding CEAC of the base-case analysis is shown
in►Fig. 2. The probability of being cost-effective for apixaban
in the base-case was 70.0 and 91.4% at a WTP threshold of
€20,000/QALY and €50,000/QALY, respectively. ►Fig. 3 repre-
sents the results of the USA. The baseline utility value has the
highest inﬂuence on the ICER (€6,721–€19,111), followed by
the apixaban unit cost (€3,619–€12,843) and the rate ofMBs in
patients with no extended treatment (€5,295–€12,836).
The results from the predictive validation against the
AMPLIFY and the AMPLIFY-EXT trials are shown in ►Tables 4
and5, respectively.All relative risks (RRs) calculated in themodel
arewithin the95%CI reported in theAMPLIFYandAMPLIFY-EXT
trials.8,9
Discussion
This CEA provides insight in the economic effects of extended
treatment with apixaban. Although exact numbers of
chronic users of apixaban or VKA as prophylaxis for VTE
events in the Netherlands is unknown,1 guidelines are very
clear: continued treatment is essential in case of recurrent
idiopathic VTE.4 Therefore, it is important to estimate the
economic effects of this treatment, especially since pre-
viously published articles on the CEA of apixaban focused
only on the short-term (6 up to 18 months) treatment.29
In the base-case analysis, extended treatment with apix-
aban versus no treatment can be considered to be cost-
effective with an ICER of €9,653/QALY when compared
with the minimal WTP threshold of €20,000/QALY, com-
monly used in the Netherlands (notably, also higher WTPs
are sometimesmentioned, such as €50,000/QALY).30 The PSA
found that apixaban in the base-case had a probability of
being cost-effective of 70.0 and 91.4% at a WTP threshold of
€20,000/QALY and €50,000/QALY, respectively. The scenario
analysis including the initial 6-month treatment as well as
the preventive extended treatment period (scenario 1)
turned out to be even more cost-effective. Scenario 2, in
which we calculated the ICER from healthcare payers’ per-
spective, was performed to make the results of the CEA
Table 3 Costs and effects per patient and incremental cost-






Base-case: Extended treatment with apixaban vs. no treat-
ment based on AMPLIFY-EXT (societal perspective)
Total costs €10,110 €6,643 €3,468




Scenario 1: Initial þ extended treatment with apixaban vs.
initial treatment with LMWH/VKA followed by no treatment
(societal perspective)
Total costs €11,203 €8,229 €2,974




Scenario 2: Base-case analysis from a healthcare payers’
perspective
Total costs €7,775 €2,570 €5,205




Scenario 3: Base-case analysis where the MB risk is equal for
apixaban and no treatment
Total costs €9,768 €5,921 €3,847




Scenario 4: Base-case analysis where the CRNMB risk is equal
for apixaban and no treatment
Total costs €10,112 €6,647 €3,466




Scenario 5: Base-case analysis where the MB and CRNMB
risks are equal for apixaban and no treatment
Total costs €9,770 €5,924 €3,845




Abbreviations: CRNMB, clinically relevant nonmajor bleeding;
LMWH, Low-molecular-weight heparin; MB, major bleeding;
QALY, quality-adjusted life-year; VKA, vitamin K antagonist.
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comparable to other countries who use this perspective, like
for example the United Kingdom. With an ICER of €14,490/
QALY, this scenario was cost-effective.
Contrary to potential expectations, the number of
patients in the AMPLIFY-EXT experiencing a MB was two
versus four in the apixaban 2.5 mg and placebo group,
respectively. The number of patients experiencing a CRNMB
was 25 for apixaban 2.5 mg and 19 in the placebo group.9
Therefore, we explored additional scenarios that assume
equivalent bleeding risks (separately for MBs and CRNMBs)
for both treatment arms. Results of these scenarios still
indicate apixaban lifelong treatment to be cost-effective
compared with no treatment, which can be explained by
the fact that these were not statistically signiﬁcant differ-
ences and would therefore not warrant such an important
effect on costs if taken as starting point for lifelong
calculations. ►Supplementary Table S3 shows that, despite
the fact that the bleeding risks are assumed equal, small
differences in bleeding numberswere still observed. This can
be explained by the fact that risks of all other events did
differ, causing different numbers of patients to be at risk of
bleeding, resulting in slightly different outcomes.
Notably, the costs per patient for bleeding events are
higher compared with costs per patient related to VTE.
Bleedings, especially IC bleeds and MB, are related to very
high expenses. Despite the fact that anticoagulation therapy
Fig. 2 The cost-effectiveness acceptability curve (CEAC)—base-case analysis. With the probabilities of being cost-effective at a WTP threshold of
€20,000/QALY and €50,000/QALY. ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
Fig. 1 Probabilistic sensitivity analysis—base-case analysis. QALY, quality-adjusted life-years.
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Table 4 Model validation comparing the results of the model to the AMPLIFY trial outcomes
AMPLIFY Model results
Apixaban LMWH/VKA RR Apixaban LMWH/VKA RR
Recurrent VTE and VTE-related death 59 71 0.83 60 72 0.83
Major bleeding 15 49 0.31 15 49 0.31
CRNMB 103 215 0.48 102 214 0.48
Treatment discontinuation 162 199 0.82 131 150 0.87
All-cause death 41 52 0.79 40 47 0.85
Abbreviations: CRNMB, clinically relevant nonmajor bleeding; LMWH, low-molecular-weight heparin; RR, relative risk; VKA, vitamin K antagonist;
VTE, venous thromboembolism.
Note: Model settings—number of patients in each treatment group: apixaban, N ¼ 2691; LMWH/VKA, N ¼ 2704; treatment duration and time
horizon ¼ 6 months.
Table 5 Model validation comparing the results of the model to the AMPLIFY-EXT trial outcomes
AMPLIFY-EXT Model results
Apixaban Placebo RR Apixaban Placebo RR
Recurrent VTE and VTE-related death 14 73 0.19 13 72 0.18
Major bleeding 2 4 0.49 2 4 0.50
CRNMB 25 19 1.29 24 19 1.26
All-cause death 32 96 0.33 31 97 0.32
Abbreviations: CRNMB, clinically relevant nonmajor bleeding; RR, relative risk; VTE, venous thromboembolism.
Notes: Model settings—number of patients in each treatment group: apixaban 2.5 mg, N ¼ 804; LMWH/VKA, N ¼ 829; treatment duration and time
horizon ¼ 12 months.
Fig. 3 Tornado diagram resulting from the univariate sensitivity analysis. DVT, deep venous thrombosis; HR, hazard ratio; IC, intracranial; MB,
major bleeding; PE, pulmonary embolism; VTE, venous thromboembolism.
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might increase costs per patient, preventing either VTE or
bleeding events is beneﬁcial for the patient’s health and
therefore these increasing costs are inferior to the overall
increase in QALYs. Another striking point in ►Table 2 is the
monitoring costs in the “no treatment” group. This can be
explained by the fact that patients who were not on treat-
ment were nevertheless at risk of recurrent VTE. All patients
who experienced a recurrent VTE in the “‘no treatment”
groupwere assumed to resume LMWH/VKA treatment since
theywere treatedwith this same treatment during the initial
treatment period (ﬁrst 6months), based on the AMPLIFYand
AMPLIFY-EXT trial.8,9 Monitoring costs of apixaban are low
compared with VKA. Therefore, the “no treatment” group
still had higher monitoring costs than the apixaban-treated
group over lifetime.
In the validation of the model (►Tables 4 and 5), most of
the RRs were comparable to the outcomes reported from the
trials, apart from all-cause mortality and treatment discon-
tinuation. The differences observed in death rates can be
attributed to the use of speciﬁc Dutch background mortality
rates. The lower number of discontinuations observed can be
attributed to patients discontinuing treatment upon the
occurrence of VTE or CRNMBs in the trial, whereas in our
modelwe allowed for these patients to remain on treatment.
Various studies already showed apixaban being cost-
effective or even cost-saving compared with LMWH/VKA in
Dutch VTE and atrial ﬁbrillation patients.10,25,31 To our
knowledge, this is the ﬁrst CEA on extended treatment
with apixaban for VTE prevention in the Netherlands.
Long-term apixaban cost-effectiveness studies have already
been conducted in the United Kingdom and Spain. Elìas et al
compared lifelong apixaban treatment with lifelong LMWH/
VKA treatment, based on the AMPLIFY and AMPLIFY-EXT
study and calculated an ICER of €4,751/QALY.32 Lanitis et al
reported an ICER of £16,944/QALY for this same scenario.29
More comparable to our study is the scenario conducted by
Lanitis et al in which initial LMWH/VKA followed by no
treatment was comparedwith extended apixaban treatment
and resulted in an ICER of £13,107/QALY. This result seems
comparable to the results of this study. Small differences in
outcomes are due to differences in costs, perspectives, uti-
lities, and background mortalities across countries.
As with all models, there are limitations to our analysis.
This study utilized a Markov approach, which is limited by
the memory-less assumption. As a result, we did not model
any further recurrent VTE events after IC bleeds, nor did we
account for an increased risk of additional recurrent VTE
once patients experienced a recurrent event. For the analysis,
we had to rely on trial data and real-world data of 528
symptomatic DVT patients combined with AMPLIFY trial
data.11 Trials are often done in controlled setting which
does not reﬂect the real-world clinical setting. In future
research, long-term use of apixaban should be followed to
determine the real-life effectiveness.
To make the results of the CEA of lifelong treatment
comparable to short-term treatment, costs were, similar to
the previously published publication, inﬂated to the year 2015
according to Dutch Statistics. The inﬂation numbers in 2016
and 2017 were relatively stable with 0.3 and 1.4%, respec-
tively.33 The assumptions made in our model are likely to be
unfavorable to apixaban given thehigher recurrent VTE reduc-
tion rates seenwith apixaban treatment.We assumed that the
origin of recurrent VTE and MB events was independent of
treatment. This assumption is similar to that used in other
models34,35 and is appropriate given that the trials were not
sufﬁcientlypowered todeterminedifferences in the individual
end-points. Beyond the 6 months of initial treatment period,
data from AMPLIFY-EXT were used to model the risk of
recurrent VTE for the next 12 months. Real-world data were
used to model the risk thereafter.11 Results might differ
between trial and real-world studies; therefore, all throm-
boembolic and bleeding risks were tested in the probabilistic
as well as the USAwhich showed to be robust.
Several sources of utility and cost values were available for
the health-states modeled. In our analysis, we used Dutch
tariffs where possible, but these were not available for all
health states. The USA shows results are most sensitive to the
baselineutility value and apixabanunit cost; however, varying
these parameters the ICER remains below the €20,000/QALY
threshold. Therefore, motivations for both under- and over-
estimation of cost-effectiveness results exist, but sensitivity
analyses examining these uncertainties did not alter the
conclusions of our analysis.
We conclude that continued apixaban treatment is a cost-
effective approach for the treatment and prevention of (recur-
rent)VTE.Moreover, results of theprobabilistic, univariate, and
scenario analyses seem very robust. These health economic
results underline the current guideline recommendation for
extended anticoagulant treatment with apixaban.3,4
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